Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: Report of two cases

Pituitary

Volumn 4, Issue 3, 2001, Pages 135-143

  Gourgiotis, Loukas ^a   Skarulis, Monica C ^b   Brucker Davis, Françoise ^d   Oldfield, Edward H ^c   Sarlis, Nicholas J ^a  

^a MSC 1276   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Octreotide; Somatostatin analogs; TSH; TSH producing pituitary tumors

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ADENOMECTOMY; ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ENDOCRINE FUNCTION TEST; FEMALE; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOTHERAPY; SURGICAL TECHNIQUE; THYROTROPIN SECRETING CELL; TUMOR GROWTH; TUMOR VOLUME;

ADENOMA; AGED; FEMALE; HORMONES; HUMANS; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 0035558663     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015358721993     Document Type: Article

References (44)

1. Central hyperthyroidism
2. Surgical treatment of thyrotropin-secreting pituitary adenomas
3. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995
4. Response of a GH-and TSH-secreting pituitary adenoma to a somatostatin analogue (SMS 201-995): Evidence that GH and TSH coexist in the same cell and secretory granules
5. Treatment of thyrotropin-secreting pituitary adenomas with octreotide
6. Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health
7. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors
8. The effect of somatostatin on the release of thyrotropin and its subunits from bovine anterior pituitary cells in vitro
9. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue
10. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
11. Complete regression of a somatotropin-secreting adenoma with lanreotide monotherapy
12. Somatostatin analogs in the treatment of acromegaly
13. Antiproliferative effect of the somatostatin analog octreotide on growth hormone-producing pituitary tumors: Results of a multicenter randomized trial
14. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human nonfunctioning pituitary adenoma cells in vitro
15. Scintigraphic imaging of pituitary adenomas: An in vivo evaluation of somatostatin receptors
16. New medical approaches in pituitary adenomas
17. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide
18. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by non functioning and gonadotropin-secreting pituitary adenomas
19. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically nonfunctioning pituitary tumors
20. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly
21. Long-acting formulations of somatostatin analogues
22. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients
23. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
24. Sandostatin LAR in acromegalic patients: Long-term treatment
25. Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1
26. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide
27. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas
28. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas
29. Simplified screening test for resistance to thyroid hormone (RTH): The T3 challenge test (T3CT)
30. Thyrotropin-secreting pituitary adenomas
31. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels
32. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
33. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroidstimulating hormone, and prolactin regulation
34. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
35. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly
36. A comparison of lanreotide and octreotide LAR for treatment of acromegaly
37. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion
38. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide
39. Thyrotropin-secreting pituitary adenomas: Clinical and biochemical heterogeneity. Case reports and follow-up of nine patients
40. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance
41. Pituitary carcinoma: A clinicopathologic study of 15 cases
42. Malignant pituitary tumors
43. Thyrotropin-secreting pituitary carcinoma
44. Octreotide as primary therapy for acromegaly